Leerink Partnrs Lowers Earnings Estimates for Quanterix

Quanterix Co. (NASDAQ:QTRX) – Investment analysts at Leerink Partnrs cut their FY2024 EPS estimates for shares of Quanterix in a research report issued on Tuesday, January 7th. Leerink Partnrs analyst P. Souda now anticipates that the company will earn ($0.94) per share for the year, down from their prior estimate of ($0.88). The consensus estimate for Quanterix’s current full-year earnings is ($0.88) per share. Leerink Partnrs also issued estimates for Quanterix’s Q4 2024 earnings at ($0.24) EPS, Q1 2025 earnings at ($0.26) EPS, Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.18) EPS and FY2025 earnings at ($0.88) EPS.

Separately, TD Cowen lifted their price target on Quanterix from $13.50 to $16.00 and gave the company a “hold” rating in a research report on Wednesday, November 13th.

Quanterix Price Performance

Shares of QTRX stock opened at $11.73 on Thursday. The stock has a market capitalization of $451.89 million, a price-to-earnings ratio of -11.17 and a beta of 1.33. The company’s fifty day simple moving average is $12.05 and its two-hundred day simple moving average is $12.70. Quanterix has a 1 year low of $9.87 and a 1 year high of $29.70.

Hedge Funds Weigh In On Quanterix

Several hedge funds and other institutional investors have recently added to or reduced their stakes in QTRX. nVerses Capital LLC purchased a new position in Quanterix in the third quarter worth $60,000. Peapack Gladstone Financial Corp purchased a new position in shares of Quanterix in the 3rd quarter worth about $131,000. Canada Pension Plan Investment Board purchased a new position in shares of Quanterix during the 2nd quarter valued at about $140,000. SG Americas Securities LLC bought a new stake in Quanterix in the 3rd quarter worth approximately $139,000. Finally, Hsbc Holdings PLC boosted its stake in Quanterix by 34.7% in the second quarter. Hsbc Holdings PLC now owns 12,738 shares of the company’s stock worth $164,000 after buying an additional 3,279 shares in the last quarter. 86.48% of the stock is currently owned by hedge funds and other institutional investors.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.